Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intellipharmaceutics International has reported net income of $1.1m for the third quarter ended 31 August 2011.
Subscribe to our email newsletter
The net income denotes $0.05 per diluted common share, compared with a loss of $2.1m or $0.19 per common share for the quarter.
The company posted loss from operations for the third quarter of 2011 stood at $1.4m compared with loss from operations of $2.1m for the three months ended 31 August 2010.
The loss for the nine months ended 31 August was $3.6m or $0.24 per common share, compared with a loss of $3.9m or $0.35 per common share for corresponding period of 2010.
Intellipharmaceutics develops and manufactures generic controlled-release and targeted-release oral solid dosage drugs.